Category Archives: TRIPS flexibilities

UN High Level Panel report is good prescription for change in access to medicines

Source: PharmaLetter | October 18, 2016 In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General’s High-Level Panel report on Access to Medicines and looks at the … Continue reading

Posted in Delinkage, R&D, TPP, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Hepatitis C: Gilead patent on sofosbuvir partially maintained following MdM patent opposition

(Paris, October 5th 2016) European Patent Office (EPO) has taken its decision following Doctors of the World – Médecins du Monde (MdM) patent opposition on Gilead Sciences’ Sofosbuvir. MdM applauds EPO’s decision to revoke partially the patent.

Posted in Hepatitis C, Patent Opposition, Patents, TRIPS flexibilities, Uncategorized | Leave a comment

Doctors push Italy to demand generics for pricey hep c drugs

By Giulia Paravicini, Politico| Sept 19, 2016 Italy’s biggest doctors association Fnomceo wants the government to make available generic versions of pricey hepatitis c drugs so more patients can have access to them. “We want to make these drugs available for … Continue reading

Posted in Compulsory Licensing, Hepatitis C, TRIPS, Uncategorized | Leave a comment

PhRMA slams Colombian efforts to cut price of cancer drug

By Suzanne Elvidge, BioPharma Dive| Sept 15, 2016 Dive Brief: Major trade organization PhRMA sharply criticized a decision by the Colombian government to reduce the price of Novartis’ cancer drug Gleevec (imatinib) in the country, calling the move a “harmful global precedent” … Continue reading

Posted in Compulsory Licensing, Drug prices, TRIPS plus, Uncategorized | Leave a comment

German Court Issues Compulsory License on HIV Drug Patent

Submitted by Andrew Goldman on 8. September 2016, Knowledge Ecology International A German patent court has ordered a compulsory license under Section 24 of the Patent Act, allowing Merck (US) to continue to market the HIV drug raltegravir (marketed as … Continue reading

Posted in Compulsory Licensing, HIV/Aids, Uncategorized | Leave a comment

Gilead using Data Exclusivity in Ukraine to monopolise Hep-C drug Sofosbuvir

Impact of data exclusivity in Ukraine on access to affordable generic version of sofosbuvir ( direct acting antiviral – DAA used for Hepatitis C treatment)  Chronology of events/facts Pharmasset originally developed Sofosbuvir. Gilead Sciences acquired Pharmasset including its Hepatititis C compounds sofosbuvir for … Continue reading

Posted in Data Exclusivity, Patent, Patent Opposition, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

India Seeks Protection With New Model Bilateral Investment Treaty

By Prabhas Ranjan, The Wire| February 2, 2016 Pricked after being sued by foreign investors under different bilateral investment treaties (BIT), India has adopted a new model. But it could impact the ongoing India-US BIT negotiations. Provoked by foreign investors suing India … Continue reading

Posted in BITS, Compulsory Licensing, TRIPS, Uncategorized, WTO | Leave a comment